Hedge fund Citadel takes short position in GSK, FT reports
FILE PHOTO: GSK (GlaxoSmithKline) logo and rising stock graph are seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/FIle photo
(Reuters) -Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times reported on Friday.
Citadel has taken a short position worth 305 million pounds ($384.5 million) in GSK stock, representing a 0.51% stake, according to data from the Financial Conduct Authority, the FT report said.
Citadel did not immediately respond to a Reuters request for comment. GSK declined comment, saying, “It is our consistent position that we do not comment on individual shareholders."
A short position represents a bet that a company's stock will fall in value. In a short sale, an investor sells borrowed stock on the bet that the shares will decline, allowing the investor to buy them back at a lower price and pocket the difference.
GSK announced a 2-billion-pound share buyback last week when it reported fourth-quarter results and lifted its long-term sales target to nearly $50 billion.
In 2024, GSK lost 7.5% of its value, underperforming rival AstraZeneca, which was down only 1.3%.
($1 = 0.7933 pounds)
(Reporting by Prerna Bedi in Bengaluru; additional reporting by Bageshri Banerjee; Editing by Alan Barona and Leslie Adler)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citadel unwinds 80% of Aschenbrenner’s portfolio risk - report
- 'Vote for Love': Magdeburg Pride crowds challenge AfD ahead of election
- Chinese robot beats Usain Bolt's 100m world record in test run
Create E-mail Alert Related Categories
Reuters, Short SalesRelated Entities
Citadel, Ken Griffin, Hedge Funds, Stock BuybackSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share